Cancer name Skin Cutaneous Melanoma
Cancer Type SKCM
Immunotherapy type Immunostimulant OR Targeting Therapy
Treatment AURKAi
Drugstatus NA
Drugbank ID NA
Checkpoints NA
Signature Type Gene
Signature Ptprc
Official Symbol PTPRC
Mode of action TRAN_NR_DOWN
Description for ‘mode of action’:the ‘mode of action’ for signature is composed of three parts: A_B_C. A describes the level at which the corresponding signature changes, it may contain the following values: TRAN(translation), PROT(protein), CE(cell), METH(methylation), AC(acetylation), PHOS(phosphorylation), MU(mutation), SNP(single nucleotide polymorphism), GLYC(glycosylation) and PATH(pathway). B describes the corresponding signature in which cancer immunotherapy condition group has changed, it may contain the following values: R (immunotherapy response group), NR(immunotherapy non-response group), D (Immunotherapy group), ND (No immunotherapy group). C describes the change detail (specific direction) of the corresponding signature, it may contain the following values: UP (High gene/protein expression or increased cellular abundance or enhanced epigenetic modification), DN (Low gene/protein expression or reduced cellular abundance or attenuated epigenetic modifications), LOSS (deletion mutation), GAIN (gain mutation),Other. For example, the search/browse detail result for CD274 was “PROT_R_UP”, it can be interpreted that the protein level of CD274 was upregulated in immunotherapy response individuals.
Experimental mouse model
Description SAM expression analysis identified a set of 544 genes whose expression statistically significantly correlated with tumor response to AURKAi with 10% false discovery rate (FDR). The expression of all 544 genes was decreased in drug-resistant tumors compared with responsive tumors. Gene Among the 544 statistically significant hits were gene encoding pan-leuko-cyte marker CD45 (Ptprc), T-cell receptor encoding genes, and cytotoxic T-cell markers such as perforin (Prf1) and Fas ligand (Fasl).
PMID 26719346
Title Connecting the Dots: Therapy-Induced Senescence and a Tumor-Suppressive Immune Microenvironment.